Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAL | P20701 | 19/20 | 0.74 |
| ▸ | ITGB2 | P05107 | 18/20 | 0.74 |
| ▸ | ICAM1 | P05362 | 18/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7144870 | 0.83 | ITGB2 (0.70) | ITGALITGB2ICAM1 | |
| SCHEMBL7143429 | 0.75 | ITGB2 (0.46) | ITGALITGB2ICAM1 | |
| SCHEMBL6069145 | 0.72 | ITGB2 (0.48) | ITGALITGB2ICAM1 | |
| SCHEMBL7170387 | 0.71 | ITGB2 (0.61) | ITGALITGB2ICAM1 | |
| SCHEMBL6198105 | 0.70 | ITGAL (0.66) | ITGALITGB2ICAM1 | |
| SCHEMBL3421675 | 0.69 | FFAR1 (0.45) | ITGALITGB2ICAM1 | |
| SCHEMBL5426358 | 0.68 | ITGB2 (0.47) | ITGALITGB2ICAM1 | |
| SCHEMBL24845310 | 0.68 | SMN1; SMN2 (0.40) | ITGALITGB2ICAM1 | |
| SCHEMBL6956020 | 0.68 | ITGB2 (0.53) | ITGALITGB2ICAM1 | |
| SCHEMBL24845072 | 0.68 | SMN1; SMN2 (0.40) | ITGALITGB2ICAM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6521619-B2 | Bind to the interaction-domain of integrin lfa-1 interrupting enothelial cell-leukocyte adhesion | ICOS CORPORATION | 2003-02-18 | — | — | US | disclosed |
| US-20020156314-A1 | Aryl phenylcyclopropyl sulfide derivatives and their use as cell adhesion inhibiting anti-inflammatory and immune suppressive agents | ICOS CORPORATION | 2002-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156314-A1 | Aryl phenylcyclopropyl sulfide derivatives and their use as cell adhesion inhibiting anti-inflammatory and immune suppressive agents | ICAM1, VCAM1, CD47 | ITGAL 166/4885ITGB2 120/4885ICAM1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.